Anti-SARS-CoV Spike (NT)

Anti-SARS-CoV Spike (NT)

Product No.: S544

[product_table name="All Top" skus="S544"]

- -
- -
Target
SARS Spike
Product Type
Polyclonal Antibody
Alternate Names
SARS-CoV Spike Antibody: E2, Spike glycoprotein, E2, S glycoprotein
Isotype
IgG
Applications
ELISA

- -
- -
Select Product Size

Data

Direct ELISA
- -
- -

Antibody Details

Product Details

Reactive Species
Virus
Host Species
Rabbit
Immunogen
Anti-SARS-CoV Spike antibody was raised against a peptide corresponding to 14 amino acids near the amino of SARS-CoV Spike glycoprotein. The immunogen is located within the first 50 amino acids of SARS-CoV Spike.
Product Concentration
1.0 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Severe Acute Respiratory Syndrome Spike (SARS Spike) recognizes an epitope near the N-terminus of SARS Spike. This polyclonal antibody was purified using affinity chromatography.
Background
A coronavirus, SARS (Severe Acute Respiratory Syndrome), was first identified 2002-2003. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately in length. SARS can be mediated by the binding of the viral spike protein, a glycosylated protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

Antigen Details

Research Area
COVID-19
.
Seasonal and Respiratory Infections
.
Viral

References & Citations

1. Marra, M. A. et al. (2003) Science 300:1399 2. Rota, P. A. et al. (2003) Science 300:1394 3. Navas-Nartin, S. R. et al. (2004) J. Neurovirol. 10:75 4. Li, W. et al. (2003) Nature 426:450
Indirect Elisa Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.